Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status

Gail J. Roboz, Farhad Ravandi, Andrew H. Wei, Hervé Dombret, Felicitas Thol, Maria Teresa Voso, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, Jianhua Zhong, C. L. Beach, Alberto Risueño, Daniel L. Menezes, Gert Ossenkoppele, Hartmut Döhner

Blood (2022) 139 (14): 2145–2155.

https://doi.org/10.1182/blood.2021013404

Published: 2022

Includes: Supplemental data

Journal Articles

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Blood (2015) 126 (3): 291–299.

https://doi.org/10.1182/blood-2015-01-621664

Published: 2015

Includes: Supplemental data

Journal Articles

A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS

Blood (2011) 118 (21): 115.

https://doi.org/10.1182/blood.V118.21.115.115

Published: 2011

Journal Articles

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Blood (2011) 117 (2): 403–411.

https://doi.org/10.1182/blood-2010-06-289280

Published: 2011

Journal Articles

Comparative Cost-Effectiveness of Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndromes (MDS).

Jeffrey D. Miller, MS, Pierre Fenaux, MD, C. L. Beach, PharmD, Risha Gidwani, DrPH, Zeba M. Khan, RPh, PhD

Blood (2009) 114 (22): 1377.

https://doi.org/10.1182/blood.V114.22.1377.1377

Published: 2009

Journal Articles

Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial

John F Seymour, MBBS, PhD, FRACP, Pierre Fenaux, MD, PhD, Lewis B. Silverman, MD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Valeria Santini, MD, Alan F. List, MD, Steven D. Gore, MD, Jay Backstrom, MD, MPH, David McKenzie, MS, C. L. Beach, PharmD

Blood (2008) 112 (11): 3629.

https://doi.org/10.1182/blood.V112.11.3629.3629

Published: 2008

Journal Articles

Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA).

Valeria Santini, MD, Pierre Fenaux, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Lewis B. Silverman, MD, Alan List, MD, Steven D. Gore, MD, John F Seymour, MBBS, PhD, FRACP, Jay Backstrom, MD, MPH, David McKenzie, MS, C. L Beach, PharmD

Blood (2008) 112 (11): 1653.

https://doi.org/10.1182/blood.V112.11.1653.1653

Published: 2008

Journal Articles

Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR)

Pierre Fenaux, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Valeria Santini, MD, Norbert Gattermann, MD, Guillermo Sanz, MD, PhD, Alan F. List, MD, Steven D. Gore, MD, John F Seymour, MBBS, PhD, FRACP, Jay Backstrom, MD, MPH, Linda Zimmerman, BSN, David McKenzie, MS, C. L. Beach, PharmD, Lewis B. Silverman, MD

Blood (2008) 112 (11): 3636.

https://doi.org/10.1182/blood.V112.11.3636.3636

Published: 2008

Journal Articles

The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)

Lewis R. Silverman, MD, Pierre Fenaux, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Valeria Santini, MD, Eva Hellström-Lindberg, MD, PhD, Norbert Gattermann, MD, Guillermo Sanz, MD, PhD, Alan F. List, MD, Steven D. Gore, MD, John F Seymour, MBBS, PhD, FRACP, Jay Backstrom, MD, MPH, David McKenzie, MS, C. L. Beach, PharmD

Blood (2008) 112 (11): 227.

https://doi.org/10.1182/blood.V112.11.227.227

Published: 2008

NARROW

Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Comparative Cost-Effectiveness of Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndromes (MDS).

Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial

Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA).

Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR)

The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only